2298
Placebo-controlled clinical trials of recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]) in patients with nonmyeloid malignancies have demonstrated significant efficacy in preventing postchemotherapy platelet nadirs of < or = 20,000/microL, and reducing the need for platelet transfusions while continuing chemotherapy without dose reductions.
 patients with nonmyeloid malignancies: Subject; nonmyeloid malignancies: Subject.Disorder; recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]): Treatment; postchemotherapy platelet nadirs of < or = 20,000/microL: Treatment.Disorder; recombinant human interleukin-11: Treatment.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with nonmyeloid malignancies: Subject; nonmyeloid malignancies: Subject.Disorder; recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]): Treatment; postchemotherapy platelet nadirs of < or = 20,000/microL: Treatment.Disorder; recombinant human interleukin-11: Treatment.Drug